NCT00303472View on ClinicalTrials.gov

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
ThrombocytopeniaMDSMyelodysplastic SyndromesRefractory Cytopenias
Interventions
DRUG

Romiplostim

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00303472 - Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter